StreetInsider.com News Articles

Candel Therapeutics Appoints Maria Ostrovsky as General Counsel

Thu, 22 Oct 2026 08:05:00 -0400

Seasoned legal and compliance executive brings global product launch, strategic transaction and international operational experience as Candel prepares for its planned Biologics License Application (BLA) submission and potential commercialization

NEEDHAM, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced the appointment of Maria Ostrovsky as General Counsel, effective November 3, 2026. Ms. Ostrovsky has 20 years of legal experience, most of it in the life sciences

Candel Therapeutics Appoints Maria Ostrovsky as General Counsel

Thu, 22 Oct 2026 08:05:00 -0400

Seasoned legal and compliance executive brings global product launch, strategic transaction and international operational experience as Candel prepares for its planned Biologics License Application (BLA) submission and potential commercialization

Jefferies Starts Candel Therapeutics Inc. (CADL) at Buy

Thu, 22 Oct 2026 04:20:40 -0400

Jefferies analyst Maury Raycroft initiates coverage on Candel Therapeutics Inc. (NASDAQ: CADL) with a Buy rating and a price target of $25.00.

The analyst comments: “CAN-2409’s (+)ve ph.III prostate data support a 4Q26 BLA and pot'l 2027/28 launch, w/ the key near-term risk shifting to completion of the remaining CMC and PrTK05 work. Intermediate-risk RT pts are the likely initial commercial focus, and recent urology launches show practices can adopt new officebased treatments, although CAN-2409’s coordination w/ RT adds complexity. AURORA study and CAN-3110 are further upside optionalities. We initiate at Buy w/ $25 PT.

CADL’s lead asset, CAN-2409, has (+)ve randomized

Jefferies Starts Candel Therapeutics Inc. (CADL) at Buy

Thu, 22 Oct 2026 04:20:40 -0400

Jefferies analyst Maury Raycroft initiates coverage on Candel Therapeutics Inc. (NASDAQ: CADL) with a Buy rating and a price target of $25.00.

CADL’s lead asset, CAN-2409, has (+)ve randomized

Form 4 Candel Therapeutics, For: Sep 30 Filed by: Loggia Nicoletta

Fri, 02 Oct 2026 17:58:00 -0400

si-local-file:///var/storage/secattach/20261002/27143798.html

Form 4 Candel Therapeutics, For: Sep 30 Filed by: PAPA JOSEPH C

Fri, 02 Oct 2026 17:57:00 -0400

si-local-file:///var/storage/secattach/20261002/27143793.html

Form 4 Candel Therapeutics, For: Sep 30 Filed by: Manning Paul B

Fri, 02 Oct 2026 17:55:00 -0400

si-local-file:///var/storage/secattach/20261002/27143784.html

Candel Therapeutics to Present at the SITC 2026 Annual Meeting

Fri, 02 Oct 2026 09:00:00 -0400

NEEDHAM, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that the Company will present data from its aglatimagene besadenovec program in non-small cell lung cancer (NSCLC) in patients with progressive NSCLC despite immune checkpoint inhibitor (ICI) treatment, as well as clinical and mechanistic findings from its phase 1b clinical trial of linoserpaturev in recurrent glioblastoma, through two accepted poster presentations at the Society for Immunotherapy of Cancer's (SITC) 41st Annual

Candel Therapeutics to Present at the SITC 2026 Annual Meeting

Fri, 02 Oct 2026 09:00:00 -0400

H.C. Wainwright Reiterates Buy Rating on Candel Therapeutics Inc. (CADL)

Fri, 02 Oct 2026 06:58:17 -0400

H.C. Wainwright analyst Andres Maldonado reiterated a Buy rating and $23.00 price target on Candel Therapeutics Inc. (NASDAQ: CADL).

The analyst commented: "Today, Candel announced publication of the final Phase 2a NSCLC clinical trial results in the Journal of ImmunoTherapy for Cancer. As previously reported, efficacy evaluable patients with unresectable stage III/IV NSCLC with stable or progressive disease on ICI demonstrated a mOS of 24.5 months (n=46, 95% CI 16.0 to 33.8) compared to historical benchmarks of current SOC with docetaxel of 9.8-11.8 months. mOS in the safety evaluable patient population, which included patients who did not receive a second injection

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 01 Oct 2026 16:05:00 -0400

NEEDHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that on September 30, 2026, the Compensation Committee of Candel’s Board of Directors (the Board) granted to 4 new employees, stock options to purchase an aggregate of 85,900 shares of the Company’s common stock, with a per share exercise price of $10.44.

The inducement stock options were made under the Company’s 2025 Inducement Plan (the Plan) and will vest

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 01 Oct 2026 16:05:00 -0400

The inducement stock options were made under the Company’s 2025 Inducement Plan (the Plan) and will vest

Candel Therapeutics publishes phase 2a NSCLC trial data in peer-reviewed journal

Thu, 01 Oct 2026 08:05:17 -0400

Candel Therapeutics, Inc. (Nasdaq: CADL) announced the publication of final phase 2a clinical trial results for aglatimagene besadenovec plus valacyclovir in patients with unresectable stage III/IV non-small cell lung cancer (NSCLC) who showed inadequate response to immune checkpoint inhibitors (ICI).

The data, published in the Journal for ImmunoTherapy of Cancer, reported a median overall survival (mOS) of 24.5 months in the evaluable population of 46 patients. Current standard-of-care docetaxel chemotherapy yields a mOS of 9.8 to 11.8 months in the same patient population, according to published trials.

Among patients with progressive disease at baseline despite ICI treatment (n=41), mOS was 21.5 months,

Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with

Thu, 01 Oct 2026 08:05:00 -0400

Peer-reviewed publication in Journal for ImmunoTherapy of Cancer reports median overall survival of 24.5 months in advanced non-small cell lung cancer (NSCLC) patients with inadequate response to immune checkpoint inhibitors (ICI)

NEEDHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced the publication of final phase 2a clinical trial results (NCT04495153) of aglatimagene besadenovec (aglatimagene) plus valacyclovir in patients with stage III/IV NSCLC who had shown

Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with

Thu, 01 Oct 2026 08:05:00 -0400

Peer-reviewed publication in Journal for ImmunoTherapy of Cancer reports median overall survival of 24.5 months in advanced non-small cell lung cancer (NSCLC) patients with inadequate response to immune checkpoint inhibitors (ICI)

NEEDHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced the publication of final phase 2a clinical trial results (NCT04495153) of aglatimagene besadenovec (aglatimagene) plus valacyclovir in patients with stage III/IV NSCLC who had shown

Candel Therapeutics reports immune activation data for prostate cancer drug

Wed, 30 Sep 2026 08:35:07 -0400

Candel Therapeutics, Inc. (Nasdaq: CADL) announced clinical and biomarker data from its phase 3 PrTK03 and phase 2 PrTK05 trials evaluating aglatimagene besadenovec in patients with intermediate-risk localized prostate cancer, according to a company press release.

In the PrTK03 phase 3 trial, 635 patients with intermediate-risk disease treated with aglatimagene plus external beam radiation therapy (EBRT) showed a 41% reduction in the risk of prostate cancer recurrence or prostate cancer-specific death compared with placebo plus EBRT, with a hazard ratio of 0.59 (95% CI 0.41–0.84; p=0.0034), based on follow-up through March 15, 2026, with a median of 58.0 months.

Exploratory analyses from

Candel Therapeutics reports immune activation data for prostate cancer drug

Wed, 30 Sep 2026 08:35:07 -0400

Exploratory analyses from

Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Can

Wed, 30 Sep 2026 08:30:00 -0400

Novel systemic immune data demonstrated T-cell activation following local administration of aglatimagene. Together with recently disclosed evidence of persistent local immune remodeling, these findings provide mechanistic support for the long-term clinical outcomes, including disease-free survival and prolonged time to biochemical failure, time to metastasis, and time to salvage anti-cancer therapy, observed in this patient population
Biodistribution and shedding data from the PrTK05 phase 2 trial remain on track for inclusion in the planned Q4 2026 Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) for localized prostate cancer
Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Can

Wed, 30 Sep 2026 08:30:00 -0400
- Novel systemic immune data demonstrated T-cell activation following local administration of aglatimagene. Together with recently disclosed evidence of persistent local immune remodeling, these findings provide mechanistic support for the long-term clinical outcomes, including disease-free survival and prolonged time to biochemical failure, time to metastasis, and time to salvage anti-cancer therapy, observed in this patient population
- Biodistribution and shedding data from the PrTK05 phase 2 trial remain on track for inclusion in the planned Q4 2026 Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) for localized prostate cancer
  
  Candel Therapeutics reports immune data for prostate cancer drug at ASTRO
  
  Wed, 30 Sep 2026 08:06:10 -0400
  
  Candel Therapeutics, Inc. (Nasdaq: CADL) presented new biomarker data from its completed phase 3 clinical trial of aglatimagene besadenovec in patients with localized intermediate- to high-risk prostate cancer at the American Society for Radiation Oncology Annual Meeting 2026.
  The data, drawn from digitized biopsy samples from 647 patients who completed a three-injection course in a randomized, placebo-controlled phase 3 study, used AI-enabled digital pathology analysis on 622 pre-treatment and 427 post-treatment biopsies collected more than two years after completion of radiation therapy.
  According to the company's findings, aglatimagene combined with external beam radiation therapy significantly increased intratumoral lymphocyte infiltration and remodeled the
  
  Candel Therapeutics reports immune data for prostate cancer drug at ASTRO
  
  Wed, 30 Sep 2026 08:06:10 -0400
  
  Candel Therapeutics, Inc. (Nasdaq: CADL) presented new biomarker data from its completed phase 3 clinical trial of aglatimagene besadenovec in patients with localized intermediate- to high-risk prostate cancer at the American Society for Radiation Oncology Annual Meeting 2026.
  The data, drawn from digitized biopsy samples from 647 patients who completed a three-injection course in a randomized, placebo-controlled phase 3 study, used AI-enabled digital pathology analysis on 622 pre-treatment and 427 post-treatment biopsies collected more than two years after completion of radiation therapy.
  According to the company's findings, aglatimagene combined with external beam radiation therapy significantly increased intratumoral lymphocyte infiltration and remodeled the
  Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026
  
  Wed, 30 Sep 2026 08:05:00 -0400
  - AI-enabled digital pathology analysis shows aglatimagene significantly increased lymphocyte infiltration and immune engagement with tumor cells compared to standard-of-care radiotherapy alone two years after treatment
  NEEDHAM, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced the presentation of new biomarker data from its completed phase 3 clinical trial of aglatimagene besadenovec (aglatimagene) in patients with localized intermediate- to high-risk prostate cancer at the American
  Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026
  
  Wed, 30 Sep 2026 08:05:00 -0400
  - AI-enabled digital pathology analysis shows aglatimagene significantly increased lymphocyte infiltration and immune engagement with tumor cells compared to standard-of-care radiotherapy alone two years after treatment
  NEEDHAM, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced the presentation of new biomarker data from its completed phase 3 clinical trial of aglatimagene besadenovec (aglatimagene) in patients with localized intermediate- to high-risk prostate cancer at the American
  BofA Securities Upgrades Candel Therapeutics Inc. (CADL) to Buy
  
  Mon, 21 Sep 2026 10:00:26 -0400
  (Updated - September 21, 2026 10:00 AM EDT)
  BofA Securities analyst Alec Stranahan upgraded Candel Therapeutics Inc. (NASDAQ: CADL) from Neutral to Buy with a price target of $18.00 (from $12.00).
  The analyst comments "We upgrade Candel to Buy (PO to $18 from $12) as a mature prostate cancer package, on track 4Q26 BLA, and $201.6M cash improve visibility ahead of potential approval next year. We model 2035 probability-adjusted sales of $1B (-$37M cons), with small changes in assumed peak share or price offering meaningfully upside given large TAM. We also raise POs across our coverage, including RevMed to $265 (from $225),
  
  BofA Securities Upgrades Candel Therapeutics Inc. (CADL) to Buy
  
  Mon, 21 Sep 2026 10:00:26 -0400
  (Updated - September 21, 2026 10:00 AM EDT)
  BofA Securities analyst Alec Stranahan upgraded Candel Therapeutics Inc. (NASDAQ: CADL) from Neutral to Buy with a price target of $18.00 (from $12.00).
  The analyst comments "We upgrade Candel to Buy (PO to $18 from $12) as a mature prostate cancer package, on track 4Q26 BLA, and $201.6M cash improve visibility ahead of potential approval next year. We model 2035 probability-adjusted sales of $1B (-$37M cons), with small changes in assumed peak share or price offering meaningfully upside given large TAM. We also raise POs across our coverage, including RevMed to $265 (from $225),

StreetInsider.com News Articles

Candel Therapeutics Appoints Maria Ostrovsky as General Counsel

Candel Therapeutics Appoints Maria Ostrovsky as General Counsel

Jefferies Starts Candel Therapeutics Inc. (CADL) at Buy

Jefferies Starts Candel Therapeutics Inc. (CADL) at Buy

Form 4 Candel Therapeutics, For: Sep 30 Filed by: Loggia Nicoletta

Form 4 Candel Therapeutics, For: Sep 30 Filed by: PAPA JOSEPH C

Form 4 Candel Therapeutics, For: Sep 30 Filed by: Manning Paul B

Candel Therapeutics to Present at the SITC 2026 Annual Meeting

Candel Therapeutics to Present at the SITC 2026 Annual Meeting

H.C. Wainwright Reiterates Buy Rating on Candel Therapeutics Inc. (CADL)

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Candel Therapeutics publishes phase 2a NSCLC trial data in peer-reviewed journal

Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with

Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with

Candel Therapeutics reports immune activation data for prostate cancer drug

Candel Therapeutics reports immune activation data for prostate cancer drug

Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Can

Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Can

Candel Therapeutics reports immune data for prostate cancer drug at ASTRO

Candel Therapeutics reports immune data for prostate cancer drug at ASTRO

Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026

Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026

BofA Securities Upgrades Candel Therapeutics Inc. (CADL) to Buy

BofA Securities Upgrades Candel Therapeutics Inc. (CADL) to Buy